# ATON Partners

ATON Partners is a Private Equity based in Auburndale, United States.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Auburndale, United States
- **Region:** North America
- **Address:** 2120 Commonwealth Avenue Suite 1 Auburndale, MA 02466
- **Founded:** 2026
- **Assets under management:** Undisclosed
- **Website:** www.atonpartners.com
- **LinkedIn:** https://www.linkedin.com/company/aton-partners

## Regulatory record

- **Reports private funds:** No

## About

ATON Partners is a Boston based private investment and management consulting firm. It offers management consulting services anchored in real life knowledge of the industry and provides management advisory services to early stage medical device and in vitro diagnostic companies while evaluating investment opportunities. With more than 20 years of operating experience, ATON Partners has a deep knowledge of building companies with innovative and medical practice-changing technologies and products.

## Sectors

- Medical Devices
- Diagnostics
- Healthcare Services

## People

- Patrick Sullivan — Co-Founder
- Daniel Levangie — Co-Founder

## Questions

### Who runs investment decisions at ATON Partners?

Investment decisions are made by co-founders Patrick Sullivan and Daniel Levangie, who share a decades-long track record operating and investing in medical-device companies. Both have led companies from concept-stage technology development through to profitable exits, most notably during their joint tenure at Cytyc Corporation and with the Bloodhound hematology platform.

### How does ATON Partners source its investments?

ATON sources opportunities through the co-founders’ individual networks built across twenty-plus years of medical-device and diagnostics operating experience. The firm’s hybrid model — offering management advisory services to early-stage companies — creates a proprietary pipeline where consulting engagements can convert into direct investment opportunities.

### What investment stages does ATON Partners target?

ATON targets early-stage companies, placing capital at the concept and early-commercialization phases of development before clinical or scale validation. The approach reflects the co-founders’ operating playbook of guiding immature technologies through regulatory approval and market adoption, as they did with Cytyc’s ThinPrep Pap Test and with Roche-acquired Bloodhound.

## Related profiles

- [Atomic Management](https://altss.com/profile/atomic-management)
- [AT PARTNERS](https://altss.com/profile/at-partners)

---

Last updated: 2026-08-11T15:06:04.815Z

Canonical page: https://altss.com/profile/aton-partners

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology